NEW YORK, Aug. 12 (GenomeWeb News) - Lynx Therapeutics said today that it has struck a deal with Pfizer to study gene expression in cell samples.
Under the arrangement, Pfizer will provide samples from normal and diseased patients for analysis by Lynx's Massively Parallel Signature Sequencing technology.
Lynx said it stands to receive payments from Pfizer for the genomics services it provides. Additional terms were not disclosed.
In 2003, Lynx has signed agreements to use its MPSS technology with Innovative Dairy Products of Australia, the Genome Institute of Singapore in transcriptome studies; Northeastern University to study the Antarctic icefish; the National Institutes on Aging; Millennium Pharmaceuticals; the Livestock Research Institute in Nairobi, Kenya; the Center for Tropical Veterinary Medicine in Edinburgh, Scotland; and the Institute for Systems Biology and IBM.